Replies to post #250541 on Anavex Life Sciences Corp (AVXL)

[frrol]

And yet most people with AD given it in a small uncontrolled trial did not show a stat-sig response, and a significant proportion withdrew consent to continue. And the millions of AD sufferers already being dosed with a lab-verified S1 agonist have not been "cured" nor deemed effectively tested.

Let's take it slowly. This is risky business and a big, controlled trial is what separates the real therapies from the amazing, can't-lose, the-science-is-amazing ones that heartbreakingly fizzle. And the latter greatly outnumber the former.

We have PDD results coming up that should be informative. It's exciting and hopefully we'll have positive signal.

[jimmy_mcyoloswag]

Sigma1 receptor activation apparently improves mitochondrial function via modulating activity at the Mitochondria-ER „docking site“ (MAM) through a host of signalling cascades related to ER-stress, inflammation, autophagy and mitochondrial homeostasis. One in particular: Calcium

The MAM:
https://www.sciencedirect.com/science/article/pii/S0005272813001850

S1r and the MAM:
https://www.sciencedirect.com/science/article/pii/S134786131400022X

Sounds to me like S1r are the mechanics at a space dock where mitochondria swing by for service..

[abew4me]

If AVXL's A2-73 results are minimal but are enough to receive some kind of approval, can they use their Rare Orphan Drug Designation to fast-track the 3-71?